Development of 2,4-Diaminopyrimidines as Antimalarials Based on Inhibition of the S108N and C59R+S108N Mutants of Dihydrofolate Reductase from Pyrimethamine-Resistant Plasmodium falciparum
- 9 February 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (6), 1244-1252
- https://doi.org/10.1021/jm010131q
Abstract
The reduced binding of pyrimethamine to Ser108Asn (S108N) mutants of parasite dihydrofolate reductase (DHFR), which forms the basis of resistance of Plasmodium falciparum to pyrimethamine, is largely due to steric constraint imposed by the bulky side chain of N108 on Cl of the 5-p-Cl-phenyl group. This and other S108 mutants with bulky side chains all showed reduced binding to pyrimethamine and cycloguanil. Less effect on binding to some bulky mutants was observed for trimethoprim, with greater flexibility for the 5-substituent. S108N DHFR also binds poorly with other pyrimethamine derivatives with bulky groups in place of the p-Cl, and the binding was generally progressively poorer for the double (C59R+S108N) mutant. Removal of the p-Cl or replacement with m-Cl led to better binding with the mutant DHFRs. Pyrimethamine analogues with unbranched hydrophobic 6-substituents showed generally good binding with the mutant DHFRs. A number of compounds were identified with high affinities for both wild-type and mutant DHFRs, with very low to no affinity to human DHFR. Some of these compounds show good antimalarial activities against pyrimethamine-resistant P. falciparum containing the mutant DHFRs with low cytotoxicity to three mammalian cell lines.Keywords
This publication has 16 references indexed in Scilit:
- Towards an understanding of drug resistance in malaria: Three-dimensional structure of Plasmodium falciparum dihydrofolate reductase by homology buildingBioorganic & Medicinal Chemistry, 1999
- Malaria: A 21st century solution for an ancient diseaseNature Medicine, 1998
- Rational Drug Design Approach for Overcoming Drug Resistance: Application to Pyrimethamine Resistance in MalariaJournal of Medicinal Chemistry, 1998
- P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolatesDrug Resistance Updates, 1998
- Mutations inPlasmodium falciparumDihydrofolate Reductase and Dihydropteroate Synthase and Epidemiologic Patterns of Pyrimethamine‐Sulfadoxine Use and ResistanceThe Journal of Infectious Diseases, 1997
- Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse originsMolecular and Biochemical Parasitology, 1997
- Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.Proceedings of the National Academy of Sciences of the United States of America, 1988
- Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum.Proceedings of the National Academy of Sciences of the United States of America, 1988
- 2,4-Diamino-5-benzylpyrimidines and analogs as antibacterial agents. 9. Lipophilic trimethoprim analogs as antigonococcal agentsJournal of Medicinal Chemistry, 1988
- The Determination of Sedimentation Constants from Fresnel Diffraction Patterns1Journal of the American Chemical Society, 1951